Gilead Says Currently No Change To FDA's Position On Overall Benefits Of Car T-Cell Therapies Outweigh Potential Risks, Including For Yescarta & Tecartus; We Remain Confident In The Overall Benefit-Risk Profile For Both Yescarta And Tecartus
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has stated that there is no change to the FDA's stance on the benefits of Car T-cell therapies, including Yescarta and Tecartus, outweighing potential risks. The company expresses confidence in the benefit-risk profile of both treatments.
January 23, 2024 | 4:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences reassures investors and patients that the FDA's view on Car T-cell therapies remains positive, which supports the continued use and potential growth of Yescarta and Tecartus.
The confirmation from Gilead Sciences regarding the FDA's unchanged position on the benefits of Car T-cell therapies is likely to maintain investor confidence in the company's products. This news reassures the market of the treatments' safety and efficacy, which could positively influence Gilead's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100